Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Théa Pharmaceuticals launches product to relieve dry eye symptoms

Manufacturer Théa Pharmaceuticals has announced the launch of a new product to provide long-lasting relief for those affected by dry eyes.

Théa Pharmaceuticals launched TheaLipid eye drops last month, marking the newest addition to the company’s preservative-free dry eye care range.

The product is clinically proven to provide long-lasting relief from symptoms of dry eye disease, meibomian gland dysfunction (MGD) and blepharitis, the manufacturer said.

The product works with a "three-in-one formula" containing natural soybean phospholipids, medium-chain triglycerides and glycerol to lubricate, restore and stabilise the tear film. This combination restores and protects the lipid layer, controls tear evaporation and provides long-lasting relief of dry eye symptoms, Théa Pharmaceuticals said.

Head of UK marketing at Théa Pharmaceuticals, Dr Matthew Olsen, said: “Eye conditions including dry eye disease and MGD can be painful and have a huge impact on a patient’s daily life.”

“The product's composition is designed to support patients and alleviate a range of eye conditions and symptoms,” he continued. 

TheaLipid has a recommended retail price of £15.49.

To order, contact your local Théa area sales manager, call 01782 381698 or email [email protected]. For further education on MGD or other eye conditions visit www.thea-pharmaceuticals.co.uk/academy.

Topics

         
Pharmacy Manager / Pharmacist
Guernsey
£70,000

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD137144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel